江苏宁沪高速公路(00177.HK)拟向集团财务公司增资6.068亿元
格隆汇7月30日丨江苏宁沪高速公路(00177.HK)发布公告,2019年07月30日,公司召开第九届董事会第十一次会议,会议审议并通过审议并通过《关于江苏宁沪高速公路股份有限公司与公司控股股东江苏交通控股有限公司共同增资江苏交通控股集团财务有限公司的关联交易议案》。
同意公司与交通控股共同增资集团财务公司,其中交通控股以人民币3.034亿元的现金方式进行增资,公司以人民币6.068亿元的现金方式进行增资;完成增资后,公司占增资后集团财务公司总股本的25%;授权董事孙悉斌、姚永嘉处理合同签署及资金拨付、审批等后续相关事宜;并将此议案提交2019年第一次临时股东大会审议。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.